A Study Evaluating the Safety and Clinical Activity of HCV-796 in Treatment-Naive and Non-Responder Subjects
NCT00367887
ABOUT THIS STUDY
FOR MORE INFORMATION
Contact a representative by phone, email, or visiting the study website. Please see the references below:
Pfizer Clinical Trials Contact Center
1-800-718-1021
- Infection with HCV genotype 1.
- HCV- infected subjects naive to treatment.
- HCV-infected non-responder subjects.
- Women who are pregnant or breastfeeding.
- ALT >/ or = 5X the upper limit of normal.
- AST >/ or = 5X the upper limit of normal.
NEED INFO?
Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center Representative

TRY A NEW SEARCH
Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your city or zip code to find studies near you.
Based on your search, you may also be interested in
- Bruxelles,
- Berlin,
- Berlin,
- Dundee,
- Bruxelles,
- La Jolla, California
- San Francisco, California
- Orlando, Florida
- Springfield, Massachusetts
- New York, New York
- New York, New York
- Tulsa, Oklahoma
- Nashville, Tennessee
- San Antonio, Texas
- Santurce,
- Anaheim, California
- La Jolla, California
- La Jolla, California
- Los Angeles, California
- Pasadena, California
- San Diego, California
- San Diego, California
- San Francisco, California
- San Francisco, California
- Washington, District of Columbia
- Gainesville, Florida
- Miami, Florida
- Atlanta, Georgia
- Louisville, Kentucky
- Boston, Massachusetts
- Worcester, Massachusetts
- Detroit, Michigan
- Plymouth, Minnesota
- St. Paul, Minnesota
- St. Louis, Missouri
- Albuquerque, New Mexico
- Bronx, New York
- Bronx, New York
- New York, New York
- New York, New York
- Chapel Hill, North Carolina
- Durham, North Carolina
- Cincinnati, Ohio
- Cleveland, Ohio
- Philadelphia, Pennsylvania
- Houston, Texas
- Annandale, Virginia
- Fairfax, Virginia
- Richmond, Virginia
- Santurce,
Descriptive Information | ||||
---|---|---|---|---|
Brief Title ICMJE | A Study Evaluating the Safety and Clinical Activity of HCV-796 in Treatment-Naive and Non-Responder Subjects | |||
Official Title ICMJE | A Phase 2, Randomized, Open-Label Study Of The Safety, Antiviral Activity, And Pharmacokinetics Of HCV-796 Administered In Combination With Peginterferon Alfa 2B (Peg-Intron) Plus Ribavirin (Rebetol) Versus Peg-Intron Plus Rebetol In Subjects With Hepatitis C Virus Genotype 1 Infection | |||
Brief Summary | This is a phase 2, randomized, open-label study comparing the safety, antiviral activity, and pharmacokinetics of HCV-796 administered in combination with peginterferon alfa 2B (Peg-Intron) plus concomitant Rebetol vs. Peg-Intron plus Rebetol in Hepatitis C Virus (HCV) genotype 1-infected subjects who are either naive to treatment or who have previously failed treatment (non-responders). | |||
Detailed Description | Not Provided | |||
Study Type ICMJE | Interventional | |||
Study Phase ICMJE | Phase 2 | |||
Study Design ICMJE | Allocation: Randomized Intervention Model: Parallel Assignment Masking: None (Open Label) Primary Purpose: Treatment | |||
Condition ICMJE | Hepatitis C | |||
Intervention ICMJE |
| |||
Study Arms ICMJE |
| |||
Publications * | Not Provided | |||
* Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline. | ||||
Recruitment Information | ||||
Recruitment Status ICMJE | Completed | |||
Actual Enrollment ICMJE | 246 | |||
Original Enrollment ICMJE | 267 | |||
Actual Study Completion Date ICMJE | July 2008 | |||
Actual Primary Completion Date | July 2008 (Final data collection date for primary outcome measure) | |||
Eligibility Criteria ICMJE | Inclusion Criteria:
Exclusion Criteria:
| |||
Sex/Gender ICMJE |
| |||
Ages ICMJE | 18 Years to 65 Years (Adult, Older Adult) | |||
Accepts Healthy Volunteers ICMJE | No | |||
Contacts ICMJE | Contact information is only displayed when the study is recruiting subjects | |||
Listed Location Countries ICMJE | Puerto Rico, United States | |||
Removed Location Countries | United Kingdom | |||
Administrative Information | ||||
NCT Number ICMJE | NCT00367887 | |||
Other Study ID Numbers ICMJE | 3173A1-200 B3381001 | |||
Has Data Monitoring Committee | No | |||
U.S. FDA-regulated Product | Not Provided | |||
IPD Sharing Statement ICMJE | Not Provided | |||
Responsible Party | Wyeth is now a wholly owned subsidiary of Pfizer | |||
Study Sponsor ICMJE | Wyeth is now a wholly owned subsidiary of Pfizer | |||
Collaborators ICMJE | ViroPharma | |||
Investigators ICMJE |
| |||
PRS Account | Wyeth is now a wholly owned subsidiary of Pfizer | |||
Verification Date | February 2013 | |||
ICMJE Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP |